Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 23, 2025 08:30 ET | Source: Tevogen Bio Inc

Tevogen Highlights Potential Role of TVGN 489 in Eliminating Persistent Viral Reservoirs Linked to Long COVID

WARREN, N.J., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today highlights emerging scientific evidence linking persistent viral...
August 11, 2025 15:45 ET | Source: Tevogen Bio Inc

Tevogen Bio Reaffirms Investor Confidence with Estimated Asset Value Exceeding $10 Billion

WARREN, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or the “Company) (Nasdaq: TVGN), reiterates investor confidence and estimated asset value over $10 billion. In...
August 11, 2025 13:24 ET | Source: Tevogen Bio Inc

REPEAT -- Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion

Treatment of a subgroup of patients with post-acute sequelae of SARS-CoV-2.Forecast adds to Tevogen Bio's Oncology therapeutic area projections of $1 billion in the launch year and $10–$14 billion...
August 11, 2025 11:58 ET | Source: Tevogen Bio Inc

Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to Follow

Total eligible patients in the US exceed 2 million.Treatment of SARS-CoV-2 infection in solid and hematologic cancer patients under active treatment.Reflects business philosophy of commercial success...
July 17, 2025 09:15 ET | Source: Tevogen Bio Inc

Tevogen Signs Letter of Intent for New In-House Cell Therapy Manufacturing Facility

WARREN, N.J., July 17, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced the signing of a letter of intent to lease a 17,428-square-foot...
May 30, 2025 11:01 ET | Source: Tevogen Bio Inc

Tevogen Details its Artificial Intelligence Initiative, Tevogen.AI; Proprietary AI-Powered Immunotherapy with Microsoft and Databricks Partnerships

WARREN, N.J., May 30, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today provided stockholders with a detailed overview of its artificial intelligence...
May 23, 2025 15:49 ET | Source: Tevogen Bio Inc

Tevogen Bio Plans to Expand Specialty Care Pipeline to Include Patients 65+, Building on Previous Forecast of Nearly $1 Billion in Launch-Year; Updated rNPV to Follow

WARREN, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced a planned expansion of TVGN 489’s target population to include...
May 22, 2025 13:21 ET | Source: Tevogen Bio Inc

Tevogen to Update on Robust Portfolio Assets, Business Expansion, Partnerships, Limited Tradable Float, High Insider Ownership and Strong Investor Confidence Ahead of June 23 Annual Meeting

WARREN, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced that it will provide several updates to stockholders in advance of...
May 12, 2025 08:00 ET | Source: Tevogen Bio Inc

Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation

WARREN, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN). As the biopharma industry faces increasing competition from international markets...
April 30, 2025 15:49 ET | Source: Tevogen Bio Inc

CD8 Technology Signs Letter of Intent for Tevogen Bio’s In-House Manufacturing Facility, Marking First Phase of Up to $50 Million Commitment

WARREN, N.J., April 30, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that CD8 Technology Services LLC (“CD8”) has signed a letter of...